UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 243

Sortiert nach

Novel agents and regimens for hematological malignancies: recent updates from 2020 ASH annual meeting

Journal of hematology and oncology, 2021-04, Vol.14 (1), p.66-25, Article 66

2021

Volltextzugriff (PDF)

A phase 1b study of venetoclax and alvocidib in patients with relapsed/refractory acute myeloid leukemia

Hematological oncology, 2023-10, Vol.41 (4), p.743-752

2023

Volltextzugriff (PDF)

A prospective study of the use of central venous catheters in patients newly diagnosed with acute myeloid leukemia treated with induction chemotherapy

Supportive care in cancer, 2022-02, Vol.30 (2), p.1673-1679

2022

Volltextzugriff (PDF)

Patient and family caregiver dyadic adherence to the allogeneic hematopoietic cell transplantation medical regimen

Psycho-oncology (Chichester, England), 2018-01, Vol.27 (1), p.354-358

2018

Volltextzugriff (PDF)

Follicular lymphoma B cells induce the conversion of conventional CD4+ T cells to T‐regulatory cells

International journal of cancer, 2009-01, Vol.124 (1), p.239-244

2009

Volltextzugriff (PDF)

S224: HIGH COMPLETE RESPONSE RATE WITH TNB‐486, A NOVEL CD19XCD3 T‐CELL ENGAGER, IN RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA: INTERIM RESULTS FROM AN ONGOING PHASE 1 STUDY

HemaSphere, 2023-08, Vol.7 (S3), p.e60614fc-n/a

2023

Volltextzugriff (PDF)

Author Correction: 6-month follow-up of VIALE-C demonstrates improved and durable efficacy in patients with untreated AML ineligible for intensive chemotherapy

Blood cancer journal (New York), 2021-10, Vol.11 (10), p.171-171, Article 171

2021

Volltextzugriff (PDF)

Long-term follow-up of VIALE-C in patients with untreated AML ineligible for intensive chemotherapy

Blood, 2022-12, Vol.140 (25), p.2754-2756

2022

Volltextzugriff (PDF)

Comparison Between the DC and AC Breakdown Characteristics of Dielectric Sheets in Liquid Nitrogen

IEEE transactions on applied superconductivity, 2014-12, Vol.24 (6), p.1-6

2014

Volltextzugriff (PDF)

A Study of the Composite Insulation Breakdown Properties for Wrapping Cables in Liquid Nitrogen

IEEE transactions on applied superconductivity, 2015-02, Vol.25 (1), p.1-6

2015

Volltextzugriff (PDF)

Prognostic significance of blast immunophenotype on first post-induction bone marrow biopsy

Leukemia & lymphoma, 2023-02, Vol.64 (3), p.750-752

2023

Volltextzugriff (PDF)

A nomogram using cytogenetics, TP53, and NPM1 mutational status can predict responses to induction chemotherapy in AML

Leukemia & lymphoma, 2022-11, Vol.63 (13), p.3257-3260

2022

Volltextzugriff (PDF)

Outcomes of Patients With Acute Myeloid Leukemia Who Relapse After 5 Years of Complete Remission

Oncology research, 2021-09, Vol.28 (7-8), p.811-814

2021

Volltextzugriff (PDF)

Results from a Real-World Multicenter Analysis of 482 Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib: A Look at Racial Differences

Targeted oncology, 2023-09, Vol.18 (5), p.727-734

2023

Volltextzugriff (PDF)

Outcomes of acute myeloid leukemia with t(15;17) not associated with acute promyelocytic leukemia

Leukemia & lymphoma, 2015-11, Vol.56 (11), p.3236-3239

2015

Volltextzugriff (PDF)

Rates and Predictors of Nonadherence to the Post-Allogeneic Hematopoietic Cell Transplantation Medical Regimen in Patients and Caregivers

Transplantation and cellular therapy, 2022-03, Vol.28 (3), p.165.e1-165.e9

2022

Volltextzugriff (PDF)

Hypomethylating Agents for Relapse after Allogeneic Hematopoietic Cell Transplantation in Myeloid Malignancies: A Case Series and Review of the Literature

Acta haematologica, 2016-01, Vol.135 (4), p.232-237

2016

Volltextzugriff (PDF)

Early CD30 signaling is critical for adoptively transferred CD4+CD25+ regulatory T cells in prevention of acute graft-versus-host disease

Blood, 2007-03, Vol.109 (5), p.2225-2233

2007

Volltextzugriff (PDF)

Gemtuzumab ozogamicin, mitoxantrone, and etoposide in newly diagnosed acute myeloid leukemia patients with persistent leukemia after a course of induction therapy

Annals of hematology, 2011-06, Vol.90 (6), p.733-735

2011

Volltextzugriff (PDF)

Interim Results of the Phase 1 Study of Tnb-486, a Novel CD19xCD3 T-Cell Engager, in Patients with Relapsed/Refractory (R/R) B-NHL

Blood, 2022-11, Vol.140 (Supplement 1), p.1474-1475

2022

Volltextzugriff (PDF)

Lemzoparlimab (lemzo) with venetoclax (ven) and/or azacitidine (aza) in patients (pts) with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS): A phase 1b dose escalation study

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.TPS7067-TPS7067

2022

Volltextzugriff (PDF)

High complete response rate with TNB-486 in relapsed/refractory follicular lymphoma: Interim results from an ongoing phase 1 study

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.7524-7524

2023

Volltextzugriff (PDF)

Differential impact of mammalian target of rapamycin inhibition on CD4+CD25+Foxp3+ regulatory T cells compared with conventional CD4+ T cells

Blood, 2008-01, Vol.111 (1), p.453-462

2008

Volltextzugriff (PDF)

Trial-in-Progress: A Phase 2 Study of Mitoxantrone, Etoposide and Gemtuzumab Ozogamicin (MEGO) for Acute Myeloid Leukemia That Persisted after the 1st Induction Regimen

Blood, 2022-11, Vol.140 (Supplement 1), p.6145-6146

2022

Volltextzugriff (PDF)

1 – 25 von 243

Suche als RSS-Feed

Aktive Filter

ThemaAged

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(223)
Mit Volltextzugriff
(227)

Publikationsform

Sprache

Englisch
(229)
Chinesisch
(12)
Japanisch
(10)

Erscheinungsjahr

n.n

Thema

Science & Technology
(165)
Life Sciences & Biomedicine
(85)
Technology
(55)
Physical Sciences
(53)
Humans
(40)
Chemistry
(35)
Materials Science
(32)
Animals
(27)
Materials Science, Multidisciplinary
(25)
Engineering
(23)
Science & Technology - Other Topics
(20)
Chemistry, Multidisciplinary
(17)
Female
(17)
Oncology
(17)
Chemistry, Physical
(16)
Nanoscience & Nanotechnology
(15)
Mice
(14)
Physics
(14)
Hematology
(13)
Male
(13)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(2)
... seit 90 Tagen
(7)

Menü

Weitere Dienste

Einstellungen

Novel agents and regimens for hematological malignancies: recent updates from 2020 ASH annual meeting

A phase 1b study of venetoclax and alvocidib in patients with relapsed/refractory acute myeloid leukemia

A prospective study of the use of central venous catheters in patients newly diagnosed with acute myeloid leukemia treated with induction chemotherapy

Patient and family caregiver dyadic adherence to the allogeneic hematopoietic cell transplantation medical regimen

Follicular lymphoma B cells induce the conversion of conventional CD4+ T cells to T‐regulatory cells

S224: HIGH COMPLETE RESPONSE RATE WITH TNB‐486, A NOVEL CD19XCD3 T‐CELL ENGAGER, IN RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA: INTERIM RESULTS FROM AN ONGOING PHASE 1 STUDY

Author Correction: 6-month follow-up of VIALE-C demonstrates improved and durable efficacy in patients with untreated AML ineligible for intensive chemotherapy

Long-term follow-up of VIALE-C in patients with untreated AML ineligible for intensive chemotherapy

Comparison Between the DC and AC Breakdown Characteristics of Dielectric Sheets in Liquid Nitrogen

A Study of the Composite Insulation Breakdown Properties for Wrapping Cables in Liquid Nitrogen

Prognostic significance of blast immunophenotype on first post-induction bone marrow biopsy

A nomogram using cytogenetics, TP53, and NPM1 mutational status can predict responses to induction chemotherapy in AML

Outcomes of Patients With Acute Myeloid Leukemia Who Relapse After 5 Years of Complete Remission

Results from a Real-World Multicenter Analysis of 482 Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib: A Look at Racial Differences

Phase 3 SELENE study: ibrutinib plus BR/R-CHOP in previously treated patients with follicular or marginal zone lymphoma

Outcomes of acute myeloid leukemia with t(15;17) not associated with acute promyelocytic leukemia

Rates and Predictors of Nonadherence to the Post-Allogeneic Hematopoietic Cell Transplantation Medical Regimen in Patients and Caregivers

Hypomethylating Agents for Relapse after Allogeneic Hematopoietic Cell Transplantation in Myeloid Malignancies: A Case Series and Review of the Literature

Early CD30 signaling is critical for adoptively transferred CD4+CD25+ regulatory T cells in prevention of acute graft-versus-host disease

Gemtuzumab ozogamicin, mitoxantrone, and etoposide in newly diagnosed acute myeloid leukemia patients with persistent leukemia after a course of induction therapy

Interim Results of the Phase 1 Study of Tnb-486, a Novel CD19xCD3 T-Cell Engager, in Patients with Relapsed/Refractory (R/R) B-NHL

Lemzoparlimab (lemzo) with venetoclax (ven) and/or azacitidine (aza) in patients (pts) with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS): A phase 1b dose escalation study

High complete response rate with TNB-486 in relapsed/refractory follicular lymphoma: Interim results from an ongoing phase 1 study

Differential impact of mammalian target of rapamycin inhibition on CD4+CD25+Foxp3+ regulatory T cells compared with conventional CD4+ T cells

Trial-in-Progress: A Phase 2 Study of Mitoxantrone, Etoposide and Gemtuzumab Ozogamicin (MEGO) for Acute Myeloid Leukemia That Persisted after the 1st Induction Regimen

Aktive Filter

Suchergebnisse filtern